Filing Flows

Filing Flows › Companies › Gyre Therapeutics › Cash flow

Gyre Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.0M in Q3 2026 · −$7.7M over twelve months

Operating cash flow−$4.0M
Capital spending−$979K
Free cash flow−$5.0M
Cash conversion cycle552 days

Analysis

In Q3 2026, Gyre Therapeutics generated −$4.0M of operating cash flow and spent $979K on capital projects, leaving free cash flow of −$5.0M. That is $1.6M less than in Q3 2025 (−$3.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$6.3M; the largest uses were operating cash flow ($6.3M), capital spending ($1.4M); besides operations, cash came from other investing ($2.8M), other financing ($2.3M); the cash balance fell by $330K.

Operating cash flow was −$4.0M against net income of −$2.5M. The largest differences: receivables −$4.5M, stock-based pay +$1.7M, payables +$1.4M.

Its cash conversion cycle was 552 days (receivables 84 + inventory 559 − payables 91).

Free cash flow

Gyre Therapeutics: free cash flow by quarterGyre Therapeutics: free cash flow by quarter−$2.7MQ4 2024−$251KQ1 2025−$7.8MQ2 2025−$3.3MQ3 2025$11.2MQ4 2025$3.0MQ1 2026−$17.0MQ2 2026−$5.0MQ3 2026
Operating cash flow less capital spending.
Gyre Therapeutics: operating cash flow against capital spendingGyre Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$2.8M−$65KQ4 2024−$129K$122KQ1 2025−$7.5M$335KQ2 2025−$2.6M$740KQ3 2025$11.2M−$7KQ4 2025$3.2M$178KQ1 2026−$16.7M$262KQ2 2026−$4.0M$979KQ3 2026
Latest (Q3 2026): Operating cash flow −$4.0M, Capital spending $979K.

Capital allocation, year by year

Gyre Therapeutics: where the cash came from (up) and went (down), by fiscal yearGyre Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingDividendsFY2021: Operating cash flow −$83.8MFY2021: Capital spending −$839KFY2021FY2022: Operating cash flow $10.7MFY2022: Asset sales $498KFY2022: Capital spending −$5.0MFY2022: Dividends −$45.0M$11.2MFY2022FY2023: Operating cash flow $25.9MFY2023: Shares issued $2.5MFY2023: Asset sales $664KFY2023: Capital spending −$8.5M$29.1MFY2023FY2024: Operating cash flow −$3.6MFY2024: Shares issued $2.6MFY2024: Asset sales $401KFY2024: Capital spending −$2.3M$3.0MFY2024FY2025: Operating cash flow $1.0MFY2025: Shares issued $2.4MFY2025: Asset sales $30KFY2025: Capital spending −$1.2M$3.4MFY2025
Over these 5 years operating cash flow totalled −$49.8M; the largest uses were operating cash flow ($87.4M) and dividends ($45.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$57.4M
Debtnone
Net cash$57.4M
Cash runway7.4 years

Gyre Therapeutics is burning cash: its operations consume cash, a free cash flow of −$7.7M a year at the current rate against $57.4M of cash and investments: a runway of about 7.4 years before any new financing.

Where the cash came from and went

Gyre Therapeutics: sources (+) and uses (−) of cash, Q3 2026Gyre Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$4.0MOther investing$2.7MCash drawn (+) / kept (−)$1.6MCapital spending−$979KExchange rates$388KShares issued$221KAsset & business sales$48K
Gyre Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Gyre Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$6.3MOther investing$2.8MOther financing$2.3MExchange rates$1.5MCapital spending−$1.4MShares issued$760KCash drawn (+) / kept (−)$330KAsset & business sales$72K

From profit to cash

Gyre Therapeutics: net income to operating cash flow, Q3 2026Gyre Therapeutics: net income to operating cash flow, Q3 2026Net income−$2.5MDepreciation & amortization$467KStock-based pay$1.7MReceivables−$4.5MInventory−$656KPayables$1.4MAccrued liabilities−$637KPrepaid and other assets$290KIncome taxes payable$643KOperating cash flow−$4.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20268455991552
Q2 20267946931517
Q1 202610878959838
Q2 2025696628723
Q1 20258171612785

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$4.0M−$979K$221K$1.6M−$5.0M
Q2 2026−$16.7M−$262K$200K$6.3M−$17.0M
Q1 2026$3.2M−$178K$21K−$431K$3.0M
Q4 2025$11.2M$7K$318K−$7.2M$11.2M
Q3 2025−$2.6M−$740K$50K−$721K−$3.3M
Q2 2025−$7.5M−$335K$23.5M−$14.1M−$7.8M
Q1 2025−$129K−$122K$1.5M−$3.2M−$251K
Q4 2024−$2.8M$65K$558K$4.1M−$2.7M

Gyre Therapeutics: income statement and cash flow

Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%. The chart follows the revenue to costs, profit and cash.

Gyre Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.